451 related articles for article (PubMed ID: 35702732)
1. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
[TBL] [Abstract][Full Text] [Related]
4. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
Milà-Alomà M; Brinkmalm A; Ashton NJ; Kvartsberg H; Shekari M; Operto G; Salvadó G; Falcon C; Gispert JD; Vilor-Tejedor N; Arenaza-Urquijo EM; Grau-Rivera O; Sala-Vila A; Sanchez-Benavides G; González-de-Echávarri JM; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Kollmorgen G; Suridjan I; Zetterberg H; Molinuevo JL; Blennow K; Suárez-Calvet M;
Neurology; 2021 Nov; 97(21):e2065-e2078. PubMed ID: 34556565
[TBL] [Abstract][Full Text] [Related]
5. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
[TBL] [Abstract][Full Text] [Related]
6. Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum.
Vilor-Tejedor N; Ciampa I; Operto G; Falcón C; Suárez-Calvet M; Crous-Bou M; Shekari M; Arenaza-Urquijo EM; Milà-Alomà M; Grau-Rivera O; Minguillon C; Kollmorgen G; Zetterberg H; Blennow K; Guigo R; Molinuevo JL; Gispert JD;
Alzheimers Res Ther; 2021 Aug; 13(1):135. PubMed ID: 34353353
[TBL] [Abstract][Full Text] [Related]
7. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
8. Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.
Milà-Alomà M; Shekari M; Salvadó G; Gispert JD; Arenaza-Urquijo EM; Operto G; Falcon C; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; González-de-Echávarri JM; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Res Ther; 2021 Jul; 13(1):134. PubMed ID: 34315519
[TBL] [Abstract][Full Text] [Related]
9. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
[TBL] [Abstract][Full Text] [Related]
10. Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
Salvadó G; Milà-Alomà M; Shekari M; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Kollmorgen G; Buckley C; Farrar G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL; Gispert JD;
Alzheimers Dement; 2021 May; 17(5):788-800. PubMed ID: 33663013
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer.
Milà-Alomà M; Salvadó G; Shekari M; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; González-de-Echávarri JM; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Suárez-Calvet M; Molinuevo JL
J Prev Alzheimers Dis; 2021; 8(1):68-77. PubMed ID: 33336227
[TBL] [Abstract][Full Text] [Related]
12. Tau-related grey matter network breakdown across the Alzheimer's disease continuum.
Pelkmans W; Ossenkoppele R; Dicks E; Strandberg O; Barkhof F; Tijms BM; Pereira JB; Hansson O
Alzheimers Res Ther; 2021 Aug; 13(1):138. PubMed ID: 34389066
[TBL] [Abstract][Full Text] [Related]
13. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
[TBL] [Abstract][Full Text] [Related]
14. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum.
Salvadó G; Milà-Alomà M; Shekari M; Ashton NJ; Operto G; Falcon C; Cacciaglia R; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Benedet AL; Kollmorgen G; Suridjan I; Wild N; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4567-4579. PubMed ID: 35849149
[TBL] [Abstract][Full Text] [Related]
15. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
Van Hulle C; Jonaitis EM; Betthauser TJ; Batrla R; Wild N; Kollmorgen G; Andreasson U; Okonkwo O; Bendlin BB; Asthana S; Carlsson CM; Johnson SC; Zetterberg H; Blennow K
Alzheimers Dement; 2021 Mar; 17(3):431-445. PubMed ID: 33336877
[TBL] [Abstract][Full Text] [Related]
16. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
17. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
Pelkmans W; Shekari M; Brugulat-Serrat A; Sánchez-Benavides G; Minguillón C; Fauria K; Molinuevo JL; Grau-Rivera O; González Escalante A; Kollmorgen G; Carboni M; Ashton NJ; Zetterberg H; Blennow K; Suarez-Calvet M; Gispert JD;
Alzheimers Dement; 2024 Jan; 20(1):483-493. PubMed ID: 37690071
[TBL] [Abstract][Full Text] [Related]
18. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
19. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
20. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
